These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19656391)

  • 1. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.
    Gray J; Chattopadhyay D; Beale GS; Patman GL; Miele L; King BP; Stewart S; Hudson M; Day CP; Manas DM; Reeves HL
    BMC Cancer; 2009 Aug; 9():271. PubMed ID: 19656391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
    Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
    BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE.
    Ferrín G; Ranchal I; Llamoza C; Rodríguez-Perálvarez ML; Romero-Ruiz A; Aguilar-Melero P; López-Cillero P; Briceño J; Muntané J; Montero-Álvarez JL; De la Mata M
    Liver Int; 2014 Mar; 34(3):438-46. PubMed ID: 23944848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.
    El-Shal AS; Zidan HE; Rashad NM; Wadea FM
    Cytokine; 2017 Aug; 96():75-86. PubMed ID: 28371666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
    Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
    Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis.
    Sorvillo F; Mazziotti G; Carbone A; Morisco F; Cioffi M; Rotondi M; Stornaiuolo G; Amato G; Gaeta GB; Caporaso N; Carella C
    Clin Endocrinol (Oxf); 2003 Feb; 58(2):207-12. PubMed ID: 12580937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma.
    Attallah AM; El-Far M; Abdel Malak CA; Farid K; Omran MM; Yahya RS; Saad EA; Albannan MS; Attallah AA; El Basuni MA; Ali IS; Abed SB; El Naggar MA
    Ann Hepatol; 2015; 14(6):869-80. PubMed ID: 26436359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations.
    Fye HK; Wright-Drakesmith C; Kramer HB; Camey S; Nogueira da Costa A; Jeng A; Bah A; Kirk GD; Sharif MI; Ladep NG; Okeke E; Hainaut P; Taylor-Robinson SD; Kessler BM; Mendy ME
    PLoS One; 2013; 8(7):e68381. PubMed ID: 23935864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
    Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
    J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma.
    Yagmur E; Rizk M; Stanzel S; Hellerbrand C; Lammert F; Trautwein C; Wasmuth HE; Gressner AM
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):755-61. PubMed ID: 17700260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
    Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
    Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients.
    Shaheen NMH; Zayed N; Riad NM; Tamim HH; Shahin RMH; Labib DA; ELsheikh SM; Moneim RA; Yosry A; Khalifa RH
    Virus Res; 2018 Aug; 255():77-84. PubMed ID: 30003924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma.
    Li H; Cui ML; Chen TY; Xie HY; Cui Y; Tu H; Chen FH; Ge C; Li JJ
    Tumour Biol; 2015 Nov; 36(11):8399-404. PubMed ID: 26018510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.
    Lewinska M; Santos-Laso A; Arretxe E; Alonso C; Zhuravleva E; Jimenez-Agüero R; Eizaguirre E; Pareja MJ; Romero-Gómez M; Arrese M; Suppli MP; Knop FK; Oversoe SK; Villadsen GE; Decaens T; Carrilho FJ; de Oliveira CP; Sangro B; Macias RIR; Banales JM; Andersen JB
    EBioMedicine; 2021 Nov; 73():103661. PubMed ID: 34740106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of serum MAGE-4 protein levels and prediction of hepatocellular carcinogenesis in patients with liver cirrhosis.
    Yutani S; Tanaka M; Mutsumoto H; Imai N; Sata M; Shichijo S; Harada M; Itoh K
    Jpn J Cancer Res; 2002 Apr; 93(4):453-8. PubMed ID: 11985796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease.
    Diaz-Sanchez A; Matilla A; Nuñez O; Rincon D; Lorente R; Lo Iacono O; Merino B; Hernando A; Campos R; Clemente G; Bañares R
    Ann Hepatol; 2013; 12(2):236-47. PubMed ID: 23396735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.